Intracranial Hemorrhage or Cerebral Infarction DRG Reimbursement

DRG 066 encompasses intracranial hemorrhage or cerebral infarction cases without Complication or Comorbidity or Major Complication or Comorbidity and defines a lower-severity inpatient category for stroke and brain hemorrhage care. Correct classification matters for inpatient reimbursement because it affects Centers for Medicare & Medicaid Services payment by reflecting expected resource use for uncomplicated presentations.

DRG 066 Overview

DRG 066 covers hospital admissions for intracranial hemorrhage or cerebral infarction without Complication or Comorbidity or Major Complication or Comorbidity. It applies to patients with primary neurologic diagnoses who do not have concurrent diagnoses that increase resource use, such as major organ failure or significant secondary complications. This Diagnosis-Related Group is important for Centers for Medicare & Medicaid Services inpatient payment because it defines a lower-severity category with expected resource consumption and influences reimbursement levels for stroke and hemorrhage care. Accurate coding of comorbid conditions determines whether admissions remain in this Diagnosis-Related Group or escalate to higher-paying groups.

Acute stroke intervention trials focusing on hyperacute thrombolytic or endovascular strategies for ischemic stroke patients presenting within the therapeutic time window; these studies enroll adults with cerebral infarction confirmed by imaging to evaluate procedural timing, selection criteria, and short-term safety outcomes (e.g., reperfusion success, intracranial hemorrhage rates). This research is relevant because it targets the inpatient period when decisions directly affect length of stay, complication rates, and immediate resource utilization that drive DRG costs and reimbursement.
Comparative effectiveness studies evaluating in-hospital management pathways for intracranial hemorrhage versus ischemic stroke without major complications, such as blood pressure management protocols, neurocritical monitoring intensity, or use of stroke units versus general wards; such trials include heterogeneous adult patients admitted for intracranial bleeding or non-complicated infarction to assess differences in functional outcomes, complication rates, and hospital resource use. Findings inform providers and payers about which inpatient care models reduce complications, readmissions, and overall cost of care within this DRG cohort.
Post-discharge transitional care and secondary prevention trials that enroll patients hospitalized with intracranial hemorrhage or cerebral infarction without CC/MCC to test interventions like coordinated discharge planning, early outpatient follow-up, rehabilitation intensity, or medication adherence programs; primary outcomes often include 30- to 90-day readmission, functional recovery, and adherence to secondary prevention. This area is important because reducing post-discharge adverse events and optimizing recovery can lower downstream utilization and financial burden for payers while improving long-term outcomes tracked after the index DRG hospitalization.

Acute stroke intervention trials focusing on hyperacute thrombolytic or endovascular strategies for ischemic stroke patients presenting within the therapeutic time window; these studies enroll adults with cerebral infarction confirmed by imaging to evaluate procedural timing, selection criteria, and short-term safety outcomes (e.g., reperfusion success, intracranial hemorrhage rates). This research is relevant because it targets the inpatient period when decisions directly affect length of stay, complication rates, and immediate resource utilization that drive DRG costs and reimbursement.
Comparative effectiveness studies evaluating in-hospital management pathways for intracranial hemorrhage versus ischemic stroke without major complications, such as blood pressure management protocols, neurocritical monitoring intensity, or use of stroke units versus general wards; such trials include heterogeneous adult patients admitted for intracranial bleeding or non-complicated infarction to assess differences in functional outcomes, complication rates, and hospital resource use. Findings inform providers and payers about which inpatient care models reduce complications, readmissions, and overall cost of care within this DRG cohort.
Post-discharge transitional care and secondary prevention trials that enroll patients hospitalized with intracranial hemorrhage or cerebral infarction without CC/MCC to test interventions like coordinated discharge planning, early outpatient follow-up, rehabilitation intensity, or medication adherence programs; primary outcomes often include 30- to 90-day readmission, functional recovery, and adherence to secondary prevention. This area is important because reducing post-discharge adverse events and optimizing recovery can lower downstream utilization and financial burden for payers while improving long-term outcomes tracked after the index DRG hospitalization.

OpenPayer

Summary & Overview

Intracranial Hemorrhage or Cerebral Infarction without CC/MCC: Inpatient Reimbursement Overview

DRG 066 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes